• Home
  • Blog
  • Events
  • Project Portfolio
  • Archive
  • Resources
  • Contact Us
WREN
  • Home
  • Blog
  • Events
  • Project Portfolio
  • Archive
  • Resources
  • Contact Us
Picture
Picture
Dr Tom Cromarty
Editor
Interests: Paediatric Emergency Medicine, Medical Engagement and Leadership, Simulation, Quality Improvement, Research 
Twitter: 
@Tomcromarty
Welsh Research and Education Network

WREN Blog

Hot topics in research and medical education, in Wales and beyond
Picture
​Dr Celyn Kenny
​Editor
Interests: Neonates, Neurodevelopment, Sepsis, Media and Broadcasting
Twitter: @Celynkenny
Picture
Dr Annabel Greenwood
Editor
Interests: Neonatology, Paediatric Emergency Medicine, Medical Education, Research, Quality Improvement
​Twitter: @an_greenwood

Archives
​

November 2020
June 2020
May 2020
April 2020
March 2020
February 2020
January 2020
December 2019
November 2019
October 2019
September 2019
August 2019
July 2019
June 2019
May 2019
April 2019
March 2019
February 2019
January 2019
December 2018
November 2018
October 2018
September 2018
August 2018
July 2018
June 2018
May 2018
April 2018
March 2018
February 2018
January 2018
December 2017
November 2017

Categories

All
A Day In The Life Of ...
Conference
Education
General
Global Health
Journal Club
Medical Leadership
News
Public Health
Research
Simulation
Trials
Wales

ECUSTEC

1/3/2018

1 Comment

 
Picture
‘Eculizumab in Shiga-Toxin producing E. Coli Haemolytic Uraemic Syndrome: A Randomised, Double-Blind, Placebo-Controlled Trial’
This is a trial currently recruiting on the Paediatric Nephrology Unit at UHW

Aim of trial:
To assess whether Eculizumab reduces the severity of Shiga-toxin producing Ecoli Haemolytic Uraemic Syndrome (STEC HUS) in children and young people
 
Background:
  • HUS - Commonest cause of intrinsic acute kidney injury in children
  • Classical triad: Microangiopathic haemolytic anaemia, thrombocytopenia, acute kidney injury
  • 95% of HUS cases occur post infection with Shiga-toxin producing E. coli (STEC) – ‘Typical’ HUS
  • ~ 120 cases/year in UK
  • 2-3% mortality rate, 50-60% of children require dialysis
  • Long term complications in ~30% of survivors e.g. CKD, permanent brain injury  
 
 
What is Eculizumab?
  • A monoclonal antibody that inhibits complement
  • Incredibly expensive
  • Already in use for the treatment of Atypical HUS
  • Previous studies into the use of Eculizumab in STEC-HUS have generated variable findings, with no objective evidence of efficacy or safety in children.  There has been no prospective, controlled trial in STEC-HUS
 
 
Primary Research Objective:
To determine whether the severity of STEC HUS is less in those given Ecu compared with those given placebo, in children aged 6m-18 years
​
-Clinical Severity Score assigned at day 60
 
Secondary Objectives:
i)To assess the safety of Ecu in STEC HUS
ii)To determine whether the incidence of CKD following STEC HUS is less in those receiving Ecu compared with those receiving placebo
iii)To evaluate the cost-effectiveness of administration of Ecu in STEC HUS from the perspective of the NHS
 
 
 
Inclusion Criteria
  • Age 6m to <19y
  • Weight ≥5kg
  • Diagnosis of HUS
                                                  - MAHA
                                                  - Thrombocytopaenia
                                                  - AKI​
  • EITHER Reported Diarrhoea within 14d prior to diagnosis​ OR stool culture/shiga toxin PCR/STEC serology result indicating STEC in the patient or household contact within 14 days prior to diagnosis of HUS
  • Patient to receive Eculizumab within 36hours of arrival to renal unit
 
Exclusion Criteria
  • Family history of aHUS
  • Previous episode of HUS
  • Known pre-existing eGFR <90ml/min/1.73m2
  • Known/suspected pneumococcal infection or meningococcal infection
  • Patient taking a drug known to be a/w HUS
  • Pregnancy
  • Malignancy
 
 
 
Active arm: Standard therapy + 1st dose Ecu Day 1, & 2nd dose Ecu Day 8
 
Control arm: Standard therapy + 1st dose placebo Day 1, & 2nd dose placebo Day 8
NB:  The trial contains an internal pilot phase of 18m (12m recruitment, 6m follow-up), the purpose of which is to determine whether the substantive trial will continue.
For further information please contact:
​ Jennifer Muller, Paediatric Research Specialist Nurse (CYARU)

Jennifer.muller@wales.nhs.uk
Annabel Greenwood
Paediatric ST3
1 Comment

Optimist-A Trial underway at University Hospital of Wales

2/1/2018

1 Comment

 
By Annabel Greenwood
Picture
Picture
Picture
The Neonatal Unit at UHW are currently participating in the ‘Optimist-A Trial’ and I thought this would be the perfect platform to raise awareness and explain briefly about the trial…
 
What is it?
An international multicentre randomised controlled trial of surfactant administration whilst on CPAP, in preterm infants 25-28/40 gestation.
 
Research Question
Does administration of exogenous surfactant using a minimally-invasive technique improve outcome in preterm infants treated with continuous positive airway pressure (CPAP)?
 
Why is it important?
Premature babies ( ≤28 weeks gestation) with significant surfactant deficiency on CPAP have historically required intubation for the administration of surfactant therapy, with subsequent increased associated risk of death, bronchopulmonary dysplasia (BPD) and other morbidities.
In an attempt to address this problem, minimally-invasive surfactant therapy (MIST) techniques have been developed whereby exogenous surfactant is administered via an instillation catheter, inserted briefly into the trachea under direct laryngoscopy, whilst on CPAP.
 
Eligibility Criteria
  • Inborn preterm infants 25-28/40 gestation
  • Age < 6 hours
  • On CPAP due to RDS
  • FiO2 ≥ 0.30
 
Randomisation
Eligible infants will be randomly allocated to receive exogenous surfactant via MIST, or continue on CPAP.
 
Intervention
  • Curosurf administration (200mg/kg) via brief tracheal catheterisation under direct visualisation, followed by recommencement of CPAP.
  • Controls continue on CPAP
  • Intervention is masked from the clinical team

Primary Outcome
  • Death or BPD at 36/40 corrected gestation
Secondary Outcomes
  • Incidence of major neonatal morbidities (intraventricular haemorrhage, periventricular leukomalacia, retinopathy of prematurity, necrotising enterocolitis)
  • Pneumothorax and patent ductus arteriosus
  • Need for intubation and surfactant therapy
  • Durations of mechanical respiratory support, intubation, CPAP, intubation and CPAP, high flow nasal cannula (HFNC), oxygen therapy, intensive care stay and hospitalisation
  • Hospitalisation cost
  • Applicability and safety of the MIST procedure
  • Outcome at 2 years
 
Any further queries?
Contact Rachel Hayward Neonatal SpR at UHW, for any further information (Rachel.hayward@doctor.org.uk)

1 Comment

New Pneumonia Trial now recruiting at the Noah’s Ark Children’s Hospital for Wales

1/12/2017

0 Comments

 
Picture
By Chris Course
 
Even though community-acquired chest infections seem to be a big chunk of the bread and butter of acute paediatrics, the optimal treatment regime for them has never really been examined – sure we all give five to seven days of amoxicillin, but do we really know why?!

A new multicenter trial called CAP-IT is underway across the UK, and the Noah’s Ark Children’s Hospital for Wales in Cardiff is one of the centres involved in recruiting patients. It’s funded by the National Institute for Health Research, and being run out of the trials unit at University College London. It’s a randomized double-blind trial looking at young children (from 6 months old to a maximum weight of 24kg) with a clinical diagnosis of community-acquired pneumonia. Patients are split into one of four treatment groups, looking at treatment with either standard dose or high dose amoxicillin for a period of three or seven days. The primary outcome measures are looking at treatment efficacy and illness duration/resolution, with secondary outcome measures looking at bacterial (pneumococcal) resistance patterns – a first for a study like this.
Picture
Picture
Picture
Once randomized, children will be followed up over a 28-day period, with telephone contact at 7, 14 and 21 days, and a face-to-face consultation at 28 days. Parents are also keeping a daily symptom diary to monitor their child’s progress, as well as filling in wellbeing questionnaires at the contact times. Pre- and post-treatment nasoparyngeal and saliva swabs are being taken to analyse bacterial resistance patterns.
 
CAP-IT is planned to be recruiting over the next two winters with a target cohort of around 2,500 children, so is still in its early phases. It’s one of the first major trials being run out of the new Children and Young People’s Research Unit, based at the Noah’s Ark Children’s Hospital for Wales. For anyone that is interested and wants to know more, or even get involved, please get in touch with WREN and we can point you in the right direction! Links to the protocol and website are included at the bottom of the article.
 
So, hopefully in a few years, we may understand this common condition a little better, but more importantly, the best way to treat it and ensure that treatment will continue working for the generations to come.
 
CAP-IT: Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community-Acquired Pneumonia (CAP): A randomized controlled trial.
 
www.capitstudy.org.uk
http://www.ctu.mrc.ac.uk/our_research/research_areas/other_conditions/studies/cap_it/
0 Comments

    Editors

    Dr Annabel Greenwood
    Dr Tom Cromarty
    ​Dr Celyn Kenny
    Dr Davide Paccagnella

    Archives

    November 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017

    Categories

    All
    A Day In The Life Of ...
    Conference
    Education
    General
    Global Health
    Journal Club
    Medical Leadership
    News
    Public Health
    Research
    Simulation
    Trials
    Wales

    RSS Feed

Last Updated 17th November 2020
​@WRENpaeds

Picture
Proudly powered by Weebly
  • Home
  • Blog
  • Events
  • Project Portfolio
  • Archive
  • Resources
  • Contact Us